- Home
- CNTX
as 05-30-2025 4:00pm EST
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 78.0M | IPO Year: | 2021 |
| Target Price: | $6.00 | AVG Volume (30 days): | 164.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.49 - $2.75 | Next Earning Date: | 05-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Context Therapeutics Inc. News
CNTX Breaking Stock News: Dive into CNTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
GlobeNewswire
19 days ago
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
24 days ago
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
GlobeNewswire
a month ago
Context Therapeutics Announces Chief Medical Officer Transition
GlobeNewswire
a month ago
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
MT Newswires
a month ago
William Blair Initiates Context Therapeutics at Outperform
GlobeNewswire
2 months ago
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
Zacks
2 months ago
Zacks.com featured highlights include Context Therapeutics, Blue Bird, Dycom Industries and Leidos
Compare CNTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CNTX Context Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.